Uchida A, Isobe Y, Asano J, Uemura Y, Hoshikawa M, Takagi M, Miura I. Targeting BCL2 with venetoclax is a promising therapeutic strategy for “double-proteinexpression” lymphoma with MYC and BCL2 rearrangements. Haematologica [Internet]. 2019Jun.30 [cited 2026Nov.11];104(7):1417-21. Available from: https://haematologica.org/article/view/8972